Cargando…
Generation of Functional CLL-Specific Cord Blood CTL Using CD40-Ligated CLL APC
Though remissions have been observed following allo-HSCT for the treatment of CLL, many CLL patients are ineligible for transplant due to the lack of HLA-compatible donors. The use of umbilical cord blood (UCB) permits transplantation of many patients who lack HLA-compatible donors due to reduced re...
Autores principales: | Decker, William K., Shah, Nina, Xing, Dongxia, Lapushin, Ruth, Li, Sufang, Robinson, Simon N., Yang, Hong, Parmar, Simrit, Halpert, Matthew M., Keating, Michael J., Gribben, John G., Molldrem, Jeffrey J., Shpall, Elizabeth J., Wierda, William G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3526610/ https://www.ncbi.nlm.nih.gov/pubmed/23284688 http://dx.doi.org/10.1371/journal.pone.0051390 |
Ejemplares similares
-
Targeting CLL-1 for acute myeloid leukemia therapy
por: Ma, Hongbing, et al.
Publicado: (2019) -
Immunotherapy in Chronic Lymphocytic Leukaemia (CLL)
por: Freeman, Ciara L., et al.
Publicado: (2016) -
Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL
por: Siddiqi, Tanya, et al.
Publicado: (2022) -
Critical appraisal of the role of rituximab in the treatment of patients with previously untreated or treated chronic lymphocytic leukemia (CLL)
por: Al-Kali, Aref, et al.
Publicado: (2010) -
CLL-033 Is COVID-19 Infection a Trigger for Progression of CLL?
por: Popov, Viola, et al.
Publicado: (2022)